Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More
Xconomy
AUGUST 26, 2016
—Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease. Morgan party. The firm has since pledged to help close the gender gap among biotech leadership.
Let's personalize your content